Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Summary
Coya Therapeutics will present the design of its ALSTARS Phase 2 trial at the ENCALS 2026 meeting in Madrid. The study evaluates COYA 302 as a treatment for ALS and focuses on regulatory T cells and neuroinflammation. The company describes COYA 302 as an investigational biologic combination therapy that is not yet FDA approved. This update highlights ongoing clinical development rather than a commercial software release or corporate transaction.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected